Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Gastro-entero-pancreatic Neuroendocrine Tumor”

18 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 18 of 18 results

Testing effectiveness (Phase 2)UnknownNCT04194125
What this trial is testing

Personalized CAPTEM Radiopeptide Therapy of Advanced, Non-resectable Neuroendocrine Cancer

Who this might be right for
Neuroendocrine Tumors
University of Warmia and Mazury 25
Not applicableNot Yet RecruitingNCT06344832
What this trial is testing

SSTR PET/CT for Preoperative N Stage Evaluation in GEP-NETs

Who this might be right for
Gastro-entero-pancreatic Neuroendocrine Tumor
Peking Union Medical College Hospital 40
Not applicableLooking for participantsNCT04949282
What this trial is testing

Spanish Series of Patients Treated With the Radionuclide Lutetium177

Who this might be right for
Neuroendocrine TumorsIntestinal NeoplasmsPancreatic Neoplasms+15 more
Sociedad Española de Medicina Nuclear e Imagen Molecular 5,000
Not applicableLooking for participantsNCT04282083
What this trial is testing

Protocol ITANET - Registry

Who this might be right for
Gastro-entero Pancreatic Neuroendocrine Tumors
Italian Association Neuroendocrine Tumors 3,600
Testing effectiveness (Phase 2)Ended earlyNCT02736448
What this trial is testing

177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) Plus Capecitabine Versus Lu-PRRT in FDG Positive, Gastro-entero-pancreatic Neuroendocrine Tumors

Who this might be right for
Gastro-entero-pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 35
Testing effectiveness (Phase 2)UnknownNCT04029428
What this trial is testing

Peptide Receptor Radionuclide Therapy in the Treatment of Advanced, Non-resectable and/or Symptomatic Tumors With SSTR Overexpression

Who this might be right for
Neuroendocrine Tumors
University of Warmia and Mazury 150
Testing effectiveness (Phase 2)Looking for participantsNCT04325425
What this trial is testing

Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary

Who this might be right for
Neuroendocrine Carcinoma
Centre Hospitalier Universitaire Dijon 218
Not applicableActive Not RecruitingNCT04727723
What this trial is testing

Italian Prospective Observational Study Assessing the Effectiveness and Outcomes Associated With Lutathera Treatment in GEP-NETs

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumor
Novartis Pharmaceuticals 164
Testing effectiveness (Phase 2)Study completedNCT02162446
What this trial is testing

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 12
Not applicableUnknownNCT01201096
What this trial is testing

Neo-adjuvant Peptide Receptor Mediated Radiotherapy With 177Lutetium in Front of Curative Intended Liver Transplantation in Patients With Hepatic Metastasis of Neuroendocrine Tumors (NEO-LEBE)

Who this might be right for
LiverMetastasisNeuroendocrine Tumors
University of Jena 50
Not applicableLooking for participantsNCT06735560
What this trial is testing

Study Assessing PET Imaging With Zirconium-labelled Girentuximab in Patients With HCC, ICC or NEN

Who this might be right for
Hepatocellular Carcinoma (HCC)Intrahepatic Cholangiocarcinoma (Icc)Neuroendocrine Tumors
Nantes University Hospital 60
Testing effectiveness (Phase 2)Study completedNCT02736500
What this trial is testing

Peptide Receptor Radionuclide Therapy With 177Lu-Dotatate Associated With Metronomic Capecitabine In Patients Affected By Aggressive Gastro-Etero-Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine TumorsGastro Entero Pancreatic Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 39
Not applicableLooking for participantsNCT06519500
What this trial is testing

Generation of Organoids of Neuroendocrine Neoplasms of the Gastro-Entero-Pancreatic Tract Obtained From Patients Undergoing Surgery

Who this might be right for
Gastro-entero-pancreatic Neoplasms
Regina Elena Cancer Institute 40
Not applicableStudy completedNCT02150408
What this trial is testing

Evaluation of PET-CT Using Somatostatin Agonists Labeled With Gallium68 in Neuroendocrine Tumors

Who this might be right for
Gastro-Entero-Pancreatic Tumors (GEPs)
Assistance Publique Hopitaux De Marseille 35
Testing effectiveness (Phase 2)Ended earlyNCT02489604
What this trial is testing

Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-DOTATATE in Advanced Gastro-entero Pancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS 70
Not applicableStudy completedNCT03288402
What this trial is testing

Investigation of the Effects of Diet on the Measurement of Plasma Chromogranin in NET Patients

Who this might be right for
Neuroendocrine Tumors
University Hospitals Coventry and Warwickshire NHS Trust 346
Testing effectiveness (Phase 2)Study completedNCT02231762
What this trial is testing

Combination of Lanreotide Autogel 120mg and Temozolomide in Progressive GEP-NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 57
Testing effectiveness (Phase 2)UnknownNCT02409849
What this trial is testing

Octreotide LAR as Maintenance Treatment for Patients With NEC

Who this might be right for
Gastro-entero-pancreatic CarcinomaEsophageal Neuroendocrine Carcinoma
Peking University 92